A Phase 1 interventional study of Pevonedistat and Rifampin in Advanced Solid Neoplasm, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-18.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
The study will enroll approximately 20 participants. The study will be conducted in two Parts: Part A and optional Part B. Part A will have a drug-drug interaction (DDI) assessment. In Part A, participants will be assigned to:
Eligible participants from Part A will continue treatment in optional Part B with pevonedistat in combination with SoC chemotherapy, docetaxel or carboplatin plus paclitaxel. The investigator will decide which SoC combination partner a participant will receive.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 18 months. Participants will make a final visit to the clinic 30 days after receiving their last dose of study drug or before the start of subsequent therapy.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria for Continuation into Optional Part B:
To be eligible for Part B, participants must have completed Part A and be reassessed to determine if they meet the continuation criteria for Part B.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pevonedistat 50 milligram per square meter (mg/m\^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
Drug: Pevonedistat · Drug: Rifampin
Pevonedistat 25 mg/m\^2 intravenously in combination with docetaxel 75 mg/m\^2 or at 20 mg/m\^2 in combination with carboplatin +paclitaxel 175 mg/m\^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
Drug: Pevonedistat · Drug: Docetaxel · Drug: Carboplatin · Drug: Paclitaxel
Pevonedistat intravenous infusion.
Also known as: MLN4924, TAK-924
Rifampin capsules.
Docetaxel intravenous infusion.
Carboplatin intravenous infusion.
Paclitaxel intravenous infusion.
Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
The Least square (LS) means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part A: Total Clearance After Intravenous Administration (CL) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part A: Volume of Distribution at Steady State After Intravenous Administration (Vss) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part A: Terminal Disposition Phase Half-life (T1/2z) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Part B: Number of Participants With Best Overall Response as Per Investigator's Assessment
Best overall response was defined as participants with best response among complete response (CR) or partial response (PR) or stable disease (SD), or progressive disease (PD). It was assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target and non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter. PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study.
Time frame: Up to Cycle 17 (end of treatment) (Cycle length =21 days)
Participants took part in the study at 4 investigative sites in the United States from 13 August 2018 to 28 February 2021.
| Milestone | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg | Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2 |
|---|---|---|---|
| Started | 20 | 0 | 0 |
| Completed | 17 | 0 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 2 | 0 | 0 |
| Milestone | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg | Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2 |
|---|---|---|---|
| Started | 0 | 9 | 8 |
| Completed | 0 | 9 | 8 |
| Not completed | 0 | 0 | 0 |
The Least square (LS) means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
| ratio | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10) | 0.962 (0.792 to 1.168) |
The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
| ratio | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10) | 0.785 (0.684 to 0.901) |
The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.
| ratio | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10) | 0.790 (0.692 to 0.902) |
| liter per hour (L/h) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Pevonedistat without rifampin (Day 1) | 35.22 ± 10.980 |
| Pevonedistat with rifampin (Day 10) | 43.77 ± 12.604 |
| liter | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Pevonedistat without rifampin (Day 1) | 312.82 ± 144.495 |
| Pevonedistat with rifampin (Day 10) | 296.10 ± 136.297 |
| hour | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Pevonedistat without rifampin (Day 1) | 7.442 ± 1.3846 |
| Pevonedistat with rifampin (Day 10) | 5.708 ± 1.3665 |
Best overall response was defined as participants with best response among complete response (CR) or partial response (PR) or stable disease (SD), or progressive disease (PD). It was assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target and non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter. PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study.
| Participants | Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5 + Paclitaxel 175 mg/m^2 |
|---|---|---|
| CR | 0 | 0 |
| PR | 2 | 1 |
| SD | 2 | 3 |
| PD | 2 | 3 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (From first dose of study drug up to Day 41 [Part A]; From first dose of study drug up to Cycle 17 Day 35 (Cycle length =21 days) [Part B]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg | 1/20 (5%) | 3/20 (15%) | 11/20 (55%) |
| Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2 | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Event | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg | Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/20 | 2/9 | 0/8 |
| Rectal haemorrhageGastrointestinal disorders | 0/20 | 0/9 | 1/8 |
| NauseaGastrointestinal disorders | 0/20 | 0/9 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/20 | 0/9 | 1/8 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/20 | 0/9 | 1/8 |
| Enterocolitis infectiousInfections and infestations | 0/20 | 1/9 | 0/8 |
| SepsisInfections and infestations | 0/20 | 1/9 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/20 | 1/9 | 0/8 |
| HypersensitivityImmune system disorders | 1/20 | 0/9 | 0/8 |
| Septic shockInfections and infestations | 1/20 | 0/9 | 0/8 |
| Event | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg | Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2 | Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2 |
|---|---|---|---|
| FatigueGeneral disorders | 3/20 | 5/9 | 2/8 |
| Peripheral sensory neuropathyNervous system disorders | 0/20 | 2/9 | 4/8 |
| Urinary tract infectionInfections and infestations | 0/20 | 4/9 | 1/8 |
| AnaemiaBlood and lymphatic system disorders | 0/20 | 0/9 | 3/8 |
| Abdominal painGastrointestinal disorders | 0/20 | 1/9 | 3/8 |
| ConstipationGastrointestinal disorders | 0/20 | 0/9 | 3/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/20 | 0/9 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 6/20 | 3/9 | 2/8 |
| PyrexiaGeneral disorders | 2/20 | 3/9 | 0/8 |
| NauseaGastrointestinal disorders | 2/20 | 2/9 | 2/8 |
The safety analysis set for Part A was defined as all enrolled participants who received at least a single pevonedistat dose during Part A.
| Age, Continuous(years) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Mean | 64.9 ± 8.70 |
| Sex: Female, Male(Participants) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Female | 10 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| United States | 20 |
| Height(centimeter (cm)) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Mean | 171.91 ± 10.235 |
| Weight(kilogram (kg)) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Mean | 87.13 ± 22.667 |
| Body Surface Area (BSA)(square meter (m^2)) | Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg |
|---|---|
| Mean | 2.03 ± 0.307 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2018 to primary completion in May 2019, 8 months.
Results were first posted in Apr 2022, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifampin
Millennium Pharmaceuticals, Inc. →